Florencia McAllister
Overview
Explore the profile of Florencia McAllister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
6698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhutani M, Faraoni E, Mork M, McAllister F
Gastrointest Endosc
. 2024 Dec;
PMID: 39653170
No abstract available.
2.
Elinav E, Devkota S, Meisel M, Zhu S, Chu H, Chen H, et al.
Immunity
. 2024 Sep;
57(9):1995-1999.
PMID: 39260349
The immune system has a vital, albeit complex, relationship with the microbes residing within us, one that we are only beginning to understand. We asked investigators what they felt were...
3.
Strickland L, Liu W, Hussein U, Mardik N, Chen X, Mills T, et al.
Cancer Prev Res (Phila)
. 2024 Aug;
17(10):457-470.
PMID: 39099209
Immunoprevention is an emerging consideration for solid tumors, including pancreatic ductal adenocarcinoma (PDAC). We and others have shown that Kras mutations in genetic models of spontaneous pancreatic intraepithelial neoplasia (PanIN),...
4.
Li L, McAllister F, Maitra A
Nat Med
. 2024 Jul;
30(8):2125-2126.
PMID: 38992125
No abstract available.
5.
Baydogan S, Mohindroo C, Hasanov M, Montiel M, Quesada P, Cazacu I, et al.
Endosc Ultrasound
. 2024 Jul;
13(2):83-88.
PMID: 38947744
Background And Objectives: Pancreatic cancer (PC) is the third cause of cancer-related deaths. Early detection and interception of premalignant pancreatic lesions represent a promising strategy to improve outcomes. We evaluated...
6.
Castro-Pando S, Howell R, Li L, Mascaro M, Faraoni E, Le Roux O, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1170-1183.
PMID: 38842383
IL17 is required for the initiation and progression of pancreatic cancer, particularly in the context of inflammation, as previously shown by genetic and pharmacological approaches. However, the cellular compartment and...
7.
Mohindroo C, Baydogan S, Agarwal P, Wright R, Prakash L, Mork M, et al.
Cancer Prev Res (Phila)
. 2024 Apr;
17(7):335-342.
PMID: 38662083
Ten percent of pancreatic neuroendocrine tumors (pNET) are related to inherited syndromes (MEN1, MEN4, VHL, NF1, and TSC). Growing evidence suggests that clinically sporadic pNETs can also harbor germline pathogenic...
8.
Herman C, Barker B, Bartelli T, Chandra V, Krajmalnik-Brown R, Jewell M, et al.
ArXiv
. 2024 Apr;
PMID: 38659636
Fecal Microbiota Transplant (FMT) is an FDA approved treatment for recurrent infections, and is being explored for other clinical applications, from alleviating digestive and neurological disorders, to priming the microbiome...
9.
Chen H, Zitvogel L, Peng Z, Yin X, McAllister F
Cell Rep Med
. 2024 Apr;
5(4):101514.
PMID: 38631286
Here, we present 3 different perspectives on how the microbiome has impacted cancer patients, treatment, and clinical studies. We hear about the challenges of implementing microbiome analyses into the clinics,...
10.
Faraoni E, McAllister F
Clin Cancer Res
. 2024 Mar;
30(11):2297-2299.
PMID: 38530840
KRT17-high intermediate cell population with elevated CXCL8 expression informed elevated myeloid infiltration status in tumors and associated with protumorigenic signatures in peripheral granulocytes from patients with pancreatic cancer. Furthermore, CXCL8...